{"title":"Cognitive","description":"","products":[{"product_id":"selank","title":"Selank","description":"\u003cdiv class=\"prod-section\"\u003e    \u003cdiv class=\"prod-section-label\"\u003e        \u003ci class=\"ti ti-file-description\"\u003e\u003c\/i\u003eResearch Background    \u003c\/div\u003e    \u003cp class=\"prod-para\"\u003e        Selank (TP-7; CAS 129954-34-3; MW 751.9 g\/mol; sequence TKPRPGP) is a synthetic 7-amino acid heptapeptide developed by the Institute of Molecular Genetics of the Russian Academy of Sciences as an analog of tuftsin, an endogenous 4-amino acid immunomodulatory peptide found in IgG antibodies. The design added a C-terminal Pro-Gly-Pro tripeptide extension to tuftsin's natural TKPR sequence — preserving the parent peptide's biological activities while conferring resistance to enzymatic degradation that would otherwise severely limit effective half-life.    \u003c\/p\u003e    \u003cp class=\"prod-para\"\u003e        Selank is approved as an anxiolytic and nootropic medication in Russia, where it has accumulated a defined safety profile through clinical use — a regulatory distinction that provides researchers with a translational framework not available for purely experimental compounds.    \u003c\/p\u003e    \u003cp class=\"prod-para\"\u003e        Mechanistically, Selank operates across overlapping neurological and immunological systems. Its primary anxiolytic mechanism involves modulation of GABA-A receptor function — increasing receptor sensitivity to GABA, producing anxiolytic and stress-relieving effects through the same receptor system targeted by benzodiazepines, but without sedation, tolerance development, or dependency risks. Independently, Selank upregulates BDNF and NGF expression, suggesting convergent anxiolytic and neurotrophic mechanisms.    \u003c\/p\u003e    \u003cp class=\"prod-para\"\u003e        The enkephalin system interaction adds another dimension: Selank stabilizes enkephalins against enzymatic degradation — extending the action of these endogenous opioid peptides and modulating their contribution to stress response regulation. Immunologically, tuftsin's parent activity (macrophage and NK cell activation) is partially preserved in Selank, creating bidirectional neuroimmune relevance for models studying stress-induced immune suppression.    \u003c\/p\u003e\n\u003c\/div\u003e\u003cdiv class=\"prod-section\"\u003e    \u003cdiv class=\"prod-section-label\"\u003e        \u003ci class=\"ti ti-atom\"\u003e\u003c\/i\u003ePhysicochemical Data    \u003c\/div\u003e    \u003cdiv class=\"table-scroll\"\u003e        \u003ctable class=\"prod-table\"\u003e            \u003cthead\u003e                \u003ctr\u003e                    \u003cth\u003eCompound\u003c\/th\u003e                    \u003cth\u003eFormula\u003c\/th\u003e                    \u003cth\u003eMW\u003c\/th\u003e                    \u003cth\u003eCAS No.\u003c\/th\u003e                    \u003cth\u003eSequence \/ Structure\u003c\/th\u003e                    \u003cth\u003eReceptor \/ Target\u003c\/th\u003e                \u003c\/tr\u003e            \u003c\/thead\u003e            \u003ctbody\u003e                \u003ctr class=\"row-alt\"\u003e                    \u003ctd class=\"td-bold\"\u003eSelank (TP-7)\u003c\/td\u003e                    \u003ctd\u003eC33H57N9O8\u003c\/td\u003e                    \u003ctd\u003e751.9 g\/mol\u003c\/td\u003e                    \u003ctd\u003e129954-34-3\u003c\/td\u003e                    \u003ctd\u003eTKPRPGP — tuftsin TKPR + Pro-Gly-Pro C-terminal extension\u003c\/td\u003e                    \u003ctd\u003eGABA-A receptor modulator; BDNF\/NGF upregulator; enkephalin stabilizer\u003c\/td\u003e                \u003c\/tr\u003e            \u003c\/tbody\u003e        \u003c\/table\u003e    \u003c\/div\u003e\n\u003c\/div\u003e","brand":"General Peptide","offers":[{"title":"1 Vial","offer_id":50856836301047,"sku":null,"price":47.0,"currency_code":"USD","in_stock":true},{"title":"3 Vials","offer_id":50856836333815,"sku":null,"price":127.0,"currency_code":"USD","in_stock":true},{"title":"5 Vials","offer_id":50856836366583,"sku":null,"price":188.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0934\/1485\/0807\/files\/Cognitive-Neuro_Selank.jpg?v=1781181268"},{"product_id":"semax","title":"Semax","description":"\u003cdiv class=\"prod-section\"\u003e\n    \u003cdiv class=\"prod-section-label\"\u003e\n        \u003ci class=\"ti ti-file-description\"\u003e\u003c\/i\u003eResearch Background\n    \u003c\/div\u003e\n\n    \u003cp class=\"prod-para\"\u003e\n        Semax (CAS 80714-61-0; MW 887.0 g\/mol; sequence MEHFPGP) is a synthetic 7-amino acid heptapeptide derived from the 4th through 7th amino acids of adrenocorticotropic hormone (ACTH) — the ACTH(4-7) fragment (Met-Glu-His-Phe) — with a C-terminal Pro-Gly-Pro tripeptide extension appended to confer enzymatic resistance against proteolytic degradation, substantially extending biologically active half-life while preserving nootropic properties without ACTH's adrenocortical hormonal activity.\n    \u003c\/p\u003e\n\n    \u003cp class=\"prod-para\"\u003e\n        Semax has undergone extensive clinical investigation in Russia, where it is approved as a nootropic and neuroprotective medication for ischemic stroke sequelae, transient ischemic attacks, and cognitive impairment states — providing a richer translational context than purely experimental compounds.\n    \u003c\/p\u003e\n\n    \u003cp class=\"prod-para\"\u003e\n        The primary and best-characterized mechanism is BDNF (Brain-Derived Neurotrophic Factor) upregulation. Multiple research and clinical studies document Semax's ability to rapidly and substantially increase BDNF expression and its high-affinity receptor TrkB in cortical, hippocampal, and striatal brain regions. BDNF is essential for synaptic plasticity, long-term potentiation, learning and memory consolidation, and neuronal survival under stress.\n    \u003c\/p\u003e\n\n    \u003cp class=\"prod-para\"\u003e\n        Simultaneously, Semax upregulates NGF and activates dopaminergic, serotonergic, and cholinergic neurotransmitter systems — producing measurable improvements in attention, memory encoding, and cognitive speed in research model and human studies.\n    \u003c\/p\u003e\n\n    \u003cp class=\"prod-para\"\u003e\n        In neuroprotection research, Semax has demonstrated significant efficacy in research subject ischemia\/reperfusion models, reducing infarct volume, improving neurological deficit scores, and enhancing post-ischemic recovery. The 25mg vial format reflects Semax research utility in extended protocols, multi-animal studies, and intranasal delivery model preparation.\n    \u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv class=\"prod-section\"\u003e\n    \u003cdiv class=\"prod-section-label\"\u003e\n        \u003ci class=\"ti ti-atom\"\u003e\u003c\/i\u003ePhysicochemical Data\n    \u003c\/div\u003e\n\n    \u003cdiv class=\"table-scroll\"\u003e\n        \u003ctable class=\"prod-table\"\u003e\n            \u003cthead\u003e\n                \u003ctr\u003e\n                    \u003cth\u003eCompound\u003c\/th\u003e\n                    \u003cth\u003eFormula\u003c\/th\u003e\n                    \u003cth\u003eMW\u003c\/th\u003e\n                    \u003cth\u003eCAS No.\u003c\/th\u003e\n                    \u003cth\u003eSequence \/ Structure\u003c\/th\u003e\n                    \u003cth\u003eReceptor \/ Target\u003c\/th\u003e\n                \u003c\/tr\u003e\n            \u003c\/thead\u003e\n\n            \u003ctbody\u003e\n                \u003ctr class=\"row-alt\"\u003e\n                    \u003ctd class=\"td-bold\"\u003eSemax\u003c\/td\u003e\n                    \u003ctd\u003eC37H51N9O10S\u003c\/td\u003e\n                    \u003ctd\u003e887.0 g\/mol\u003c\/td\u003e\n                    \u003ctd\u003e80714-61-0\u003c\/td\u003e\n                    \u003ctd\u003eMEHFPGP — ACTH(4-7) fragment + Pro-Gly-Pro extension\u003c\/td\u003e\n                    \u003ctd\u003eBDNF\/NGF upregulator; dopaminergic\/serotonergic activator; neuroprotective\u003c\/td\u003e\n                \u003c\/tr\u003e\n            \u003c\/tbody\u003e\n        \u003c\/table\u003e\n    \u003c\/div\u003e\n\u003c\/div\u003e","brand":"General Peptide","offers":[{"title":"1 Vial","offer_id":50856838627575,"sku":null,"price":47.0,"currency_code":"USD","in_stock":true},{"title":"3 Vials","offer_id":50856838660343,"sku":null,"price":127.0,"currency_code":"USD","in_stock":true},{"title":"5 Vials","offer_id":50856838693111,"sku":null,"price":188.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0934\/1485\/0807\/files\/Cognitive-Neuro_Semax.jpg?v=1781181392"},{"product_id":"pe-22-28","title":"PE-22-28","description":"\u003cdiv class=\"prod-section\"\u003e\n    \u003cdiv class=\"prod-section-label\"\u003e\n        \u003ci class=\"ti ti-file-description\"\u003e\u003c\/i\u003eResearch Background\n    \u003c\/div\u003e\n\n    \u003cp class=\"prod-para\"\u003e\n        PE-22-28 is a 7-amino acid synthetic analog of spadin that functions as an antagonist of TREK-1, a two-pore domain K2P potassium channel encoded by the KCNK2 gene. TREK-1 channels normally regulate neuronal excitability and suppress serotonergic neuron activity within the raphe nuclei. By inhibiting this channel, PE-22-28 increases serotonin availability and has demonstrated rapid antidepressant-like effects in preclinical models. The peptide has also been associated with enhanced hippocampal BDNF expression and neuroplastic adaptations, making it a valuable research tool for investigations involving depression, anxiety, neurogenesis, and cognitive function.\n    \u003c\/p\u003e\n\n    \u003cp class=\"prod-para\"\u003e\n        This synthetic spadin analog represents a distinct strategy for mood disorder research by targeting ion channel function rather than directly inhibiting monoamine reuptake. TREK-1 channels contribute to the maintenance of neuronal resting membrane potential and help regulate serotonin neuron firing rates. Antagonism of these channels disinhibits serotonergic signaling pathways, resulting in increased serotonin release and downstream molecular responses involved in neuronal adaptation.\n    \u003c\/p\u003e\n\n    \u003cp class=\"prod-para\"\u003e\n        In research applications, PE-22-28 has demonstrated rapid antidepressant-like activity in behavioral models, often producing measurable effects within hours rather than the prolonged onset typically observed with conventional SSRI compounds. Experimental findings suggest that its activity involves both acute enhancement of serotonergic transmission and longer-term neuroplastic changes, including increased expression of brain-derived neurotrophic factor (BDNF) within the hippocampus. This combination of neurotransmitter modulation and neurotrophic support distinguishes it from traditional antidepressant approaches.\n    \u003c\/p\u003e\n\n    \u003cp class=\"prod-para\"\u003e\n        The peptide's mechanism may also complement other neuromodulatory compounds because it operates through potassium channel blockade rather than receptor agonism or neurotransmitter reuptake inhibition. This unique pathway provides opportunities for research exploring synergistic mechanisms underlying mood regulation, stress resilience, cognitive performance, and neural plasticity.\n    \u003c\/p\u003e\n\n    \u003cdiv class=\"prod-table-wrap\"\u003e\n        \u003ctable class=\"prod-table\"\u003e\n            \u003cthead\u003e\n                \u003ctr\u003e\n                    \u003cth\u003eCompound\u003c\/th\u003e\n                    \u003cth\u003eMW \/ Formula\u003c\/th\u003e\n                    \u003cth\u003eCAS No.\u003c\/th\u003e\n                    \u003cth\u003eSequence \/ Structure\u003c\/th\u003e\n                    \u003cth\u003eReceptor \/ Target\u003c\/th\u003e\n                \u003c\/tr\u003e\n            \u003c\/thead\u003e\n            \u003ctbody\u003e\n                \u003ctr\u003e\n                    \u003ctd\u003ePE-22-28\u003c\/td\u003e\n                    \u003ctd\u003e~800 g\/mol (estimated)\u003c\/td\u003e\n                    \u003ctd\u003e-\u003c\/td\u003e\n                    \u003ctd\u003e7-amino acid synthetic spadin analog; TREK-1 antagonist\u003c\/td\u003e\n                    \u003ctd\u003eTREK-1 K2P channel blocker; serotonin enhancer; neuroplasticity promoter\u003c\/td\u003e\n                \u003c\/tr\u003e\n            \u003c\/tbody\u003e\n        \u003c\/table\u003e\n    \u003c\/div\u003e\n\u003c\/div\u003e","brand":"General Peptide","offers":[{"title":"1 Vial","offer_id":50856852422903,"sku":null,"price":40.0,"currency_code":"USD","in_stock":true},{"title":"3 Vials","offer_id":50856852455671,"sku":null,"price":108.0,"currency_code":"USD","in_stock":true},{"title":"5 Vials","offer_id":50856852488439,"sku":null,"price":160.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0934\/1485\/0807\/files\/Cognitive-Neuro_PE-22-28.jpg?v=1781184576"}],"url":"https:\/\/generalpeptide.com\/collections\/cognitive.oembed","provider":"General Peptide","version":"1.0","type":"link"}